Gastroenterology
Volume 141, Issue 6 , Pages 1963-1967 , December 2011

Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?

  • Pratima Sharma
  • ,
  • Anna S. Lok

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Anna S. Lok, MD, Alice Lohrman Andrews Research Professor in Hepatology, University of Michigan Health System, 1500 E Medical Center Drive, 3912, Taubman Center, SPC 5362, Ann Arbor, Michigan 48109. fax: (734) 936-7392

  • Image Result

    HCV replication cycle, the potential drug targets and a list of DAAs in phase II/III clinical trials (data available at: www.clinicaltrials.gov). The steps of HCV replication cycle include cell bindin

    HCV replication cycle, the potential drug targets and a list of DAAs in phase II/III clinical trials (data available at: www.clinicaltrials.gov). The steps of HCV replication cycle include cell binding and entry into the hepatocyte, followed by uncoating of HCV and transfer of HCV RNA into endoplasmic reticulum where polyprotein translation and protein processing occurs. This is followed by viral transcription, assembly and export. (Adapted from Lindenbach and Rice4 and Schlutter5). IRES, internal ribosome entry site; LDL, low density lipoprotein; NKT, natural killer T-cell; NS, nonstructural; VLDL, very low density lipoprotein.

 Conflict of interest Dr Lok receives research grant support from Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Roche, and Merck, and has served on the advisory/Data and Safety Monitoring Panel for Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, and Roche.

 Funding Dr Sharma is supported by National Institutes of Health (NIH) grant KO8 DK-088946.

PII: S0016-5085(11)01463-6

doi: 10.1053/j.gastro.2011.10.020

Gastroenterology
Volume 141, Issue 6 , Pages 1963-1967 , December 2011